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One of the ways to reduce chronic P. aeruginosa (Pa) infection in cystic ﬁbrosis
patients, is early treatment. This study evaluated both the infection-free period
following successive episodes of colonization and treatment efﬁcacy. Patients were
treated with oral ciproﬂoxacin and nebulized colistin twice a day for the ﬁrst
isolation. If eradication failed, we continued to treat patients with oral ciproﬂoxacin
and nebulized tobramycin for 28 days. Pa was considered eradicated after 3
consecutive negative respiratory cultures over 6 months. We treated a total of
88 episodes of ﬁrst Pa colonization in 88 patients; 64 (84%) of the 88 episodes
were treated with success, 12 (13.6%) failed. A second episode of colonization,
after a mean infection-free period of 32.2 months, occurred in 49 (55.6%) out of
88 patients. Therapy was successful in 37 (75.5%) out of 49 patients, failed in
9 (18.3%). Furthermore 29 (32.9%) of 88 patients experienced a third colonization
episode which occurred after a mean infection-free interval of 23 months. Therapy
was successful in 19 (65.5%) out of 29 patients, failed in 6 (20.6%) but 15 (17%)
of 88 patients experienced a fourth colonization episode after a mean infection-
free interval of 18 months. Therapy was successful in 13 (86.6%) of 15 cases and
failed in 2 (13.3%). There were no statistically signiﬁcant differences in the number
of successfully treated episodes according to different treatments. The infection-
free period signiﬁcantly decreased between colonization episodes (p = 0.02). The
percentage of success was not statistically different between episodes of successive
colonizations. Early eradication treatment provided long infection-free periods
although they became signiﬁcantly shorter with recurring colonization.
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Background: PA with HMP is associated with high antibiotic resistance rates in
CF. AIM Determine occurrence and antibiotic resistance PA HMPs in Italian CF
pts.
Methods: 154 non-mucoid, 100 mucoid and 18 SCV non-multiresistant PA from
170 pts from 4 Italian CF Centers were studied. HMP was determined as previously
described (Macia MD) by disk-diffusion and Etest for 10 antibiotic; results were
read after 24 h at 35ºC; plates were re-incubated for further 12 h and HMPs were
deﬁned as strains showing a sub-population grown after 36 h and resistant to 3 or
more antibiotics. The genetic relationship of all PA was determined by BOX-PCR.
Results: 32% of pts was colonized with HMPs, mean age 28 yrs; pts without HMPs
showed a mean age of 17 yrs. HMPs distribution was 17% in non-mucoid, 28% in
mucoid and 39% in SCV strains. No correlation with HMP occurrence and shared
genotypes was found. The % of antibiotic resistance in HMPs was AK 33, TO 12,
CL9, FEP 51, CAZ 41, MEM 26, P/T42, T/C 47, CIP 35 and LEV 39.
Conclusion: The occurrence of 32% found, conﬁrm previous rates reported from
CF pts in other country (Oliver A.). The high occurrence found of in mucoid (28%)
and SCV (39%) strains, typical in long term chronic colonization, stress the possible
role of CF lung environment in inducing the expression of HMPs. In these strains
the emerging resistance to TO and particularly to CL is worrisome for antimicrobial
treatment implications.
Supported by: Italian Cystic Fibrosis Foundation Grant.
74 Antibiotic resistance and hypermutator P. aeruginosa
D.J. Waine1,3, D. Honeybourne1, J. Whitehouse1, G. Smith2, C.G. Dowson3.
1Adult CF Unit, Heart of England NHS Trust, Birmingham, United Kingdom;
2Dept Microbiology, Heart of England NHS Trust, Birmingham, United Kingdom;
3Biological Sciences, Warwick University, Coventry, United Kingdom
Introduction: Hypermutator P. aeruginosa constitutes an important part of the CF
lung microbiology. Previous studies found that the presence of resistant mutant
subpopulations (RMS: colonies growing in the zone of inhibition of an antibiotic
disc on agar) can be used to test for them, and that they were associated with
increased antibiotic resistance. We tested these ﬁndings in our adult CF patients.
Methods: 161 isolates from 40 patients were collected over 6 months. Hypermuta-
tors were detected according to previously published methods [1]. Each isolate had
susceptibility testing (agar disc-diffusion method) to 9 antibiotics. The presence of
RMS in 5 antibiotic zones was tested in a subset of 40 isolates.
Results: 47 (29.2%) isolates were hypermutators, and these were isolated from
16 (40.0%) patients. Mucoid isolates were more likely to be hypermutators than non-
mucoid (42.5% vs 16.0%, p< 0.001, Chi2), but hypermutator phenotype was not
associated with small colony variants (p = 0.778, Chi2) or the number of antibiotics
(0−9) isolates were resistant to (p = 0.864, Mann-Whitney). Hypermutators were
more likely to have RMS to 3 or more antibiotics (45% vs 10%, p = 0.013, Chi2).
Receiver-operator curves for RMS as a test of hypermutator phenotype had area
under the curve of 70%.
Conclusions: This is the ﬁrst report of an association between hypermutator and
mucoid phenotypes. Hypermutators were associated with the presence of RMS
but, contrary to previous ﬁndings [1], the association with RMS was not speciﬁc
enough to use it as a test for the hypermutator phenotype and hypermutators were
not resistant to more antibiotics.
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Introduction: Acquisition and spread of metallo-b-lactamases (MBLs), conferring
resistance to nearly all b-lactams including carbapenems, is a matter of major
concern. MBL-producing Pseudomonas aeruginosa strains are reported in hospital
outbreaks worldwide, but very rarely from cystic ﬁbrosis (CF) patients. The aim of
this work was to assess the prevalence, persistence and genetic support of MBLs
in P. aeruginosa from chronically colonized patients of CF Center of Florence and
to analyse potential correlation with antibiotic treatment and patient outcome.
Methods: Forty carbapenem-resistant isolates of P. aeruginosa from 35 CF patients
were assayed for MBL production by Etest and spectrophotometric assays. MBL
genes and their genetic support were characterised by PCR and DNA sequencing.
When MBL production was detected, multiple isolates from the same patient were
retrospectively analysed. Clonality of the MBL-producing strains was investigated
by RAPD.
Results: MBL activity was detected in 2 of 40 (5%) strains, obtained from
2 patients, which harboured the blaVIM−1 and blaVIM−2 gene respectively. Carriage
of the same MBL variant by isolates from the same patient was detected over
a prolonged period. Consecutive isolates either belonged in the same clone (for
blaVIM−2) or in 2 different clones (for blaVIM−1). The 2 blaVIM genes were carried
on different class 1 integrons.
Conclusions: Two distinct variants of the blaVIM resistance gene were detected
in P. aeruginosa from CF patients over a prolonged period. The emergence of
acquired MBL genes in P. aeruginosa in such patients is a phenomenon that could
have important implications on surveillance protocols and clinical management.
